Cargando…
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). Here, we analyzed the relationship between MYCN amplification (MNA) status and neuroblastoma prognosis. We scre...
Autores principales: | Yagyu, Shigeki, Iehara, Tomoko, Tanaka, Shiro, Gotoh, Takahiro, Misawa-Furihata, Akiko, Sugimoto, Tohru, London, Wendy B., Hogarty, Michael D., Teramukai, Satoshi, Nakagawara, Akira, Hiyama, Eiso, Maris, John M., Hosoi, Hajime |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981470/ https://www.ncbi.nlm.nih.gov/pubmed/27513929 http://dx.doi.org/10.1371/journal.pone.0161039 |
Ejemplares similares
-
RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker
por: Misawa, A, et al.
Publicado: (2009) -
MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening
por: Iehara, T, et al.
Publicado: (2006) -
Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma
por: Tomida, Akimasa, et al.
Publicado: (2021) -
A phase II JN-I-10 efficacy study of IDRF-based surgical decisions and stepwise treatment intensification for patients with intermediate-risk neuroblastoma: a study protocol
por: Iehara, Tomoko, et al.
Publicado: (2020) -
The Role of MYCN in Symmetric vs. Asymmetric Cell Division of Human Neuroblastoma Cells
por: Izumi, Hideki, et al.
Publicado: (2020)